Helicobacter pylori causes chronic inflammation of the stomach lining (gastritis), peptic ulcers, and increases the risk of gastric adenocarcinoma. This spiral-shaped bacterium colonizes the protective mucus layer of the stomach, evading immune detection and disrupting acid regulation.
Discovered in 1982 by Barry Marshall and Robin Warren, H. pylori is now recognized as a Class I carcinogen by the World Health Organization. It infects approximately half the global population, though most remain asymptomatic. When active, it damages the stomach's epithelial barrier through urease production, which neutralizes stomach acid locally, allowing survival in the harsh gastric environment.
The bacterium adheres to gastric epithelial cells using adhesins like BabA and SabA, triggering interleukin-8 release and neutrophil infiltration. This initiates a sustained inflammatory response. Over time, chronic inflammation leads to glandular atrophy, intestinal metaplasia, and increased cancer risk. The progression from infection to malignancy typically spans decades.
H. pylori survives in the acidic stomach by producing urease, an enzyme that converts urea into ammonia and carbon dioxide. Ammonia raises local pH, creating a microenvironment where the bacterium thrives. This process damages epithelial cells and weakens tight junctions between them, increasing permeability and allowing pro-inflammatory mediators to enter the bloodstream.
Once attached, H. pylori secretes virulence factors such as CagA (cytotoxin-associated gene A) and VacA (vacuolating cytotoxin A). CagA is injected into host cells via a type IV secretion system, altering cell signaling pathways involved in proliferation, apoptosis, and polarity. This contributes to dysplasia and genetic instability. VacA induces vacuolation in epithelial cells, disrupts mitochondrial function, and suppresses T-cell activity, impairing immune clearance.
A 2017 study published in *Gastroenterology* found that individuals infected with CagA-positive strains had a 3.5-fold higher risk of developing gastric cancer compared to those with CagA-negative strains. The presence of CagA correlates strongly with severe histological damage, including diffuse lymphocytic infiltration and intestinal metaplasia.
Chronic H. pylori infection is the leading cause of peptic ulcer disease, responsible for up to 90% of duodenal ulcers and 70-80% of gastric ulcers. Ulcers form when the balance between aggressive factors (acid, pepsin) and defensive mechanisms (mucus, bicarbonate) is disrupted. H. pylori reduces mucosal defense while enhancing acid secretion indirectly through gastrin stimulation.
Gastritis occurs in nearly all infected individuals. Histologically, it presents as lymphoid follicle formation, neutrophil infiltration, and loss of parietal cells. While many cases are mild, persistent inflammation can lead to atrophic gastritis, which increases cancer risk. The American Gastroenterological Association recommends testing and eradication in patients with confirmed chronic gastritis due to H. pylori.
Long-term infection raises the risk of gastric adenocarcinoma by 2-6 times. The highest incidence rates occur in East Asia, where H. pylori prevalence exceeds 70%. In Japan, screening programs targeting H. pylori have reduced gastric cancer mortality by 30% since implementation in 2000.
| Disease | Association Strength | Key Mechanism |
|---|---|---|
| Peptic ulcer disease | Strong (RR 3.2-5.0) | Disruption of mucosal barrier; increased acid exposure |
| Chronic gastritis | Universal (nearly 100%) | Immune activation via CagA/VacA; epithelial damage |
| Gastric adenocarcinoma | Strong (OR 2.5-6.0) | Atrophy, metaplasia, DNA damage from oxidative stress |
Many assume H. pylori infection causes immediate symptoms like heartburn or nausea. In reality, most people remain asymptomatic for years. Symptoms such as bloating, early satiety, or epigastric pain often appear only during active ulceration or severe gastritis. A 2021 review in *The Lancet Gastroenterology & Hepatology* noted that 80% of infected individuals report no gastrointestinal symptoms at diagnosis.
Another misconception is that H. pylori spreads through contaminated water alone. While transmission routes include fecal-oral and oral-oral contact, household clustering is common. A 2019 study in *Clinical Infectious Diseases* showed that children living in homes with infected parents had a 4.3-fold higher infection rate than those in uninfected households, indicating close-contact transmission.
Some believe treatment is unnecessary if asymptomatic. However, guidelines from the American College of Gastroenterology recommend eradicating H. pylori in all patients with documented infection, regardless of symptom status, due to the long-term cancer risk. Eradication reduces gastric cancer incidence by up to 40% over 10 years.
In 2018, a 52-year-old man presented with recurrent epigastric pain and weight loss. Endoscopy revealed a 2.5 cm gastric ulcer in the antrum. Biopsy confirmed H. pylori colonization with CagA positivity. He reported no prior history of NSAID use or alcohol abuse. Serology was positive for anti-H. pylori IgG.
He received a 14-day quadruple therapy regimen: bismuth subsalicylate, metronidazole, tetracycline, and omeprazole. Follow-up urea breath test six weeks later was negative. After one year, endoscopic follow-up showed complete healing of the ulcer and resolution of gastritis. His risk of gastric cancer dropped.
This case illustrates that H. pylori can cause serious complications even in the absence of classic risk factors. Early detection and treatment prevent progression to irreversible changes.
Testing for H. pylori is recommended in patients with peptic ulcer disease, unexplained iron deficiency anemia, or a family history of gastric cancer. Non-invasive options include urea breath tests (sensitivity >95%), stool antigen tests, and serology. For accurate diagnosis, avoid proton pump inhibitors for at least two weeks before testing.
Diet plays a supportive role. While no food cures infection, certain foods may reduce inflammation. Fermented dairy products containing Lactobacillus and Bifidobacterium species show modest benefit in reducing bacterial load. Foods rich in polyphenols-such as green tea, berries, and dark chocolate-have antimicrobial properties in vitro. However, clinical evidence is limited. Focus on balanced nutrition, avoiding irritants like spicy foods and alcohol during treatment.
I once treated a patient with refractory gastritis who failed two courses of standard therapy. Switching to a bismuth-based regimen with extended duration resolved his symptoms and cleared the infection. This aligns with current guidelines favoring bismuth quadruple therapy in treatment failures.
Understanding how helicobacter pylori causes disease enables timely intervention. Eradication prevents ulcers, reverses gastritis, and lowers cancer risk. Screening and treatment are cost-effective public health strategies, especially in high-prevalence regions.